Cosmetics Standard 2007

The instrument rests on a small number of legal and technical concepts that determine its operation.

Cosmetic product categories and types: Schedule 1 enumerates discrete categories and types, for example face and nail (tinted bases or foundations with sunscreen; lip products with sunscreen) (Schedule 1 item 1), skin care (moisturisers with sunscreen; sunbathing products with SPF 4-15) (Schedule 1 item 2), antibacterial skin products (item 3), anti‑acne products (item 4), oral hygiene products (item 5), and anti‑dandruff products (item 6). The operative obligation in s 4 ties compliance to those enumerated items.

Incorporation by reference to AS/NZS standards: the Standard relies on external technical documents. Section 3 expressly defines AS/NZS 2604:1998 and AS/NZS 2604:2012 by title and, for 2012, by publication date. The Schedule specifies which clauses or tables from those standards govern labelling, protection factor statements, performance requirements for broad‑spectrum products, and label content if a protection factor is stated (Schedule 1 items 1 and 2 refer to clauses 5, 6, 7.1, 7.3, Table 1 in clause 5.2, and clause 6.3 of AS/NZS 2604:2012, and clauses 6.2, 6.3 and clause 7 of AS/NZS 2604:1998 where applicable).

Temporal and transitional differentiation: for certain products the Schedule distinguishes between products imported into, or manufactured in, Australia before 1 August 2018 and those imported or manufactured on or after that date. The applied requirements are materially different in some respects depending on that date. For example, Schedule 1 item 1 (tinted bases and lip products with sunscreen) permits compliance with either AS/NZS 2604:1998 or AS/NZS 2604:2012 for products before 1 August 2018, but for products on or after that date it requires AS/NZS 2604:2012 and additional labelling/performance obligations (Schedule 1 item 1). Item 2 (moisturising products with sunscreen and certain sunbathing products) follows a similar bifurcation, with the later date imposing stricter and more specific requirements (Schedule 1 item 2).

Representational limits: several items in Schedule 1 are framed in terms of how the product is "presented" and which claims may or may not be made. For example item 3 requires antibacterial skin products to be presented as active only against bacteria and not presented as active against viruses, fungi or other microbial organisms, or for use in connection with disease, or for use in procedures involving blood contact or injections. Item 4 requires anti‑acne products to be presented as controlling or preventing acne only through cleansing, moisturising, exfoliating or drying the skin. Item 5 requires oral hygiene products to claim only benefits consequential on improvements to oral hygiene, and not broader disease claims. Item 6 requires anti‑dandruff products to be presented as controlling or preventing dandruff only through cleansing, moisturising, exfoliating or drying the scalp (Schedule 1 items 3-6).

Labelling and packaging criteria: the Schedule sets specific labelling and pack‑size limits, including a prohibition on presenting certain skin care products as water‑resistant, a cap on pack size at 300 mL or 300 g for some skin care items, and an expiry date requirement if the product is not stable for at least 36 months (Schedule 1 item 2(b)(iii)-(iv)). Where a protection factor is stated, the Schedule imports clauses of the AS/NZS standard that govern how that protection factor must be stated on the label (Schedule 1 items 1 and 2).

Separation from therapeutic claims: the Schedule explicitly disallows therapeutic claims for certain categories. For example, item 2(b)(v) bars therapeutic claims, including any representation about skin cancer, for specified skin care products that contain sunscreen (Schedule 1 item 2(b)(v)). The instrument therefore draws a line in presentation and labelling between permitted cosmetic representations and disallowed therapeutic representations, at least for the categories enumerated.

In operation these concepts combine: the category identifies the product, the relevant AS/NZS clauses specify performance and labelling standards, temporal rules determine which version or clauses apply, and representational limits constrain marketing. Section 4 is the statutory switch that requires compliance with the standards listed for the product type.

The Standard allocates direct obligations and consequential compliance responsibilities across the cosmetics supply chain. The primary legal addressees are persons or entities that import into, or manufacture in, Australia cosmetics of the product categories and types specified in Schedule 1. Section 4 operates on a product basis: "A cosmetic of a product category and type mentioned in an item of Schedule 1 must comply with the standards mentioned in the item." That language imposes the compliance duty on the product, which in practical regulatory terms falls to those who place the product on the Australian market , importers and manufacturers.

Suppliers, distributors and retailers are affected indirectly. They must ensure the cosmetics they offer to the Australian market comply with the Schedule 1 requirements, because non‑compliant products risk regulatory enforcement under the parent Act and will have to be removed or corrected. The Schedule’s emphasis on how a product is "presented" (for example items 3-6) means that marketing, labelling and advertising agencies that draft packaging copy and promotional materials influence whether a product falls within or outside the permitted presentation envelope.

Testing laboratories and conformity-assessment providers are implicated where compliance requires meeting performance criteria in AS/NZS 2604:1998 or AS/NZS 2604:2012. The Schedule requires, for specified products, compliance with performance requirements for broad‑spectrum products and with clause‑specific labelling criteria in those AS/NZS standards (Schedule 1 items 1 and 2). Entities providing SPF measurement, broad‑spectrum testing, stability testing (for the 36‑month stability threshold) and other analytical services will supply the evidence manufacturers and importers need to justify label claims and to establish compliance.

Consumers are affected in that the instrument governs what representations may be made about certain cosmetics, the maximum SPF presentation permitted for some skin care products, and packaging/expiry disclosures. That outcome affects what consumers see on labels and the durability and claimed performance of products sold as cosmetics.

Regulators and compliance officers within agencies administering the Industrial Chemicals (Notification and Assessment) Act 1989 are affected because the Standard is made under that Act and therefore becomes an instrument that those agencies must consider when assessing compliance for cosmetics captured by the Act and the Standard (instrument header; s 4). Finally, manufacturers and importers of sunscreen-containing cosmetics face particular transitional choices depending on whether products are manufactured or imported before or on/after 1 August 2018, because the Schedule conditions differ by date for items 1 and 2.

Duties

• Compliance obligation: Section 4 places a mandatory duty on cosmetics of the product categories and types listed in Schedule 1 to comply with the standards stated in the relevant Schedule item. The obligation is product‑based and applies to cosmetics "of a product category and type mentioned in an item of Schedule 1" (s 4).

• Meeting AS/NZS requirements: For sunscreen‑containing face, nail and lip products (Schedule 1 item 1) and for certain skin care products with sunscreen (Schedule 1 item 2), the duty is to meet specified parts of AS/NZS 2604:1998 or AS/NZS 2604:2012 depending on manufacture/import date. For products imported into, or manufactured in, Australia before 1 August 2018, compliance may be with either the 1998 or 2012 AS/NZS standard as set out in the Schedule. For products imported into, or manufactured in, Australia on or after 1 August 2018, AS/NZS 2604:2012 is required and additional clause‑specific requirements apply (Schedule 1 items 1 and 2).

• Labelling and protection factor statements: When a product’s label states a protection factor, the Schedule requires compliance with specific clauses of the applicable AS/NZS standard governing how protection factors and equivalent category descriptions are to be stated (Schedule 1 items 1 and 2 refer to clauses 6.2 and 6.3 of AS/NZS 2604:1998; clauses 5 and 6 of AS/NZS 2604:2012; and for post‑2018 products clauses 7.1 and 7.3 of AS/NZS 2604:2012 where a protection factor is stated).

• Broad‑spectrum performance: For certain products imported or manufactured on or after 1 August 2018, the product must meet the AS/NZS 2604:2012 performance requirements for a broad‑spectrum product, specifically Table 1 in clause 5.2 and clause 6.3 (Schedule 1 item 1(d) and item 2(c)).

• Pack size, water‑resistance and expiry requirements: For specified skin care products (Schedule 1 item 2(b)), the product must not be presented as having SPF greater than 15, must not be presented as water‑resistant, and if the product is not stable for at least 36 months it must include an expiry date or use‑by date on its label; pack size must not exceed 300 mL or 300 g (Schedule 1 item 2(b)(i)-(iv)).

• Prohibition of therapeutic claims: For certain skin care products with sunscreen, the Schedule bars therapeutic claims, including any representation about skin cancer (Schedule 1 item 2(b)(v)). Other items (3-6) similarly restrict presentations that would amount to medical or therapeutic claims by limiting the mechanisms or benefits that may be asserted.

• Representational limits on antimicrobial and other claims: Item 3 mandates that antibacterial skin products be presented as active only against bacteria and forbids presentation as active against viruses, fungi or other microbes, or for use in connection with disease, piercing, medical procedures involving blood contact, or pre‑contact with persons accessing health services. Item 4 restricts anti‑acne product presentation to the named non‑therapeutic mechanisms. Item 5 restricts oral hygiene claims to benefits consequential on oral hygiene, and item 6 restricts anti‑dandruff products to non‑therapeutic mechanisms.

Rights and corollary features

• Right to rely on specified standards: The Schedule provides a clear compliance pathway. For products manufactured or imported before 1 August 2018, in some cases the Schedule allows compliance with either AS/NZS 2604:1998 or AS/NZS 2604:2012 (Schedule 1 items 1 and 2). That dual‑version allowance gives manufacturers and importers a defined right to meet either standard for pre‑2018 products where the Schedule so provides.

• Predictability through clause reference: By tying obligations to specific clauses and tables in the AS/NZS standards, the instrument gives businesses a precise technical benchmark (for labelling and performance) rather than a generalised performance obligation. Those clause references form the evidentiary standard for demonstrating compliance with the Schedule.

• Transitional certainty: The Schedule’s bifurcation by manufacture/import date supplies a temporal right to continue manufacturing or importing under the older compliance pathway for products placed on the market before the 1 August 2018 threshold where the Schedule allows it. That temporal delineation is a discrete procedural right embedded in the Schedule’s terms.

• Burden of proof implicit: Although the Standard does not expressly allocate the burden of proof, the practical effect is that manufacturers and importers must demonstrate compliance with the referenced clauses and with the representational limits in Schedule 1. Meeting the clause‑specific labelling and performance requirements in AS/NZS 2604:2012 or 1998 will be the primary method of demonstrating compliance under s 4 and Schedule 1.

The instrument does not set out appeal rights, authorisations, exemptions or administrative review mechanisms in its text. Any such procedural rights and remedies would rest in the parent Act or other legislative instruments rather than in this Standard. The Schedule’s textual specificity, especially in referencing clause‑level labelling and performance criteria, effectively makes the listed AS/NZS clauses the compliance specification for covered products.

The Standard itself contains no express penalty clauses, infringement schedules or enforcement procedures. The instrument is made under subsection 81(1) of the Industrial Chemicals (Notification and Assessment) Act 1989, as recorded at the top of the compiled instrument. Because the Standard is an instrument made under that Act, enforcement, sanctions, and any criminal or civil penalties available for non‑compliance will stem from the parent Act and any enforcement provisions incorporated into it, not from the Standard’s text itself. The Standard functions as a binding technical and representational requirement for the specified cosmetics, while the Act provides the statutory machinery for compliance, notification, assessment and, potentially, enforcement.

Practical enforcement levers and evidence expectations that are implicit in the Standard’s text include:

• Testability via AS/NZS clauses: The Schedule requires compliance with specified clauses and tables in AS/NZS standards (Schedule 1 items 1 and 2). Those clause references create testable performance and labelling standards that enforcement agencies can verify by inspection of labels, product specifications, laboratory reports and stability testing.

• Representational assessment: For items that regulate presentation and claims (items 3-6), enforcement will focus on the product packaging, marketing materials and any promotional content to determine whether a product is "presented as" something outside the permitted envelope. The Schedule lists precise prohibited presentations, for example claims of activity against viruses or claims connected with disease (Schedule 1 item 3(b)(i)-(iii) etc.). Enforcement will therefore involve a documentary and factual inquiry into how the product is marketed.

• Transitional compliance checks: Because some items distinguish between products depending on whether they were manufactured or imported before or on/after 1 August 2018, enforcement will require evidence establishing the date of manufacture or import. Supply chain records, invoices, customs or production logs may be needed to prove which regime applied.

Absent textual penalty provisions, the Standard relies on the parent Act’s enforcement mechanisms. The Standard does not set civil pecuniary penalties, infringement notices or recall powers itself. Users must consult the Industrial Chemicals (Notification and Assessment) Act 1989 and any other relevant regulatory instruments for the precise enforcement powers, offences and sanctioning procedures that apply when a product fails to meet the Schedule’s requirements.

The Standard is an instrument subordinate to the Industrial Chemicals (Notification and Assessment) Act 1989, and its primary legal interaction is with that parent statute. The compiled instrument explicitly states it was made under subsection 81(1) of the Act (instrument header). Section 4 frames obligations by reference to Schedule 1, but it does not itself displace or replicate the enforcement, notification or assessment mechanisms that the Act governs. Therefore the Standard operates as a technical regulatory specification within the statutory framework established by the Act.

Interaction with external technical standards and private standards‑setting: The Standard incorporates by reference two editions of a private technical standard, AS/NZS 2604:1998 and AS/NZS 2604:2012 (s 3). By doing so, the Standard creates a legal effect for those privately published standards. Compliance with particular clauses in the AS/NZS standards is made mandatory for specified product types. Practically, entities must obtain and follow those external documents to meet the statutory requirement in s 4. The Standard therefore creates legal obligations that are implemented by private standard text; access to and interpretation of those private standards is essential to legal compliance.

Boundary with therapeutic or medical regulation: The Schedule expressly bars therapeutic claims in certain contexts. For example, Schedule 1 item 2(b)(v) states that specified skin care products "must not have a therapeutic claim, including any representation about skin cancer, made for it." That prohibition defines a regulatory boundary in presentation between permitted cosmetic claims and claims that would be therapeutic in character. While the Standard itself does not state the other regime that would apply to therapeutic goods, the instrument’s prohibition on therapeutic claims creates a definitional effect: products that make therapeutic claims will not comply with the cosmetic representations permitted by Schedule 1 and therefore may fall outside the Standard’s safe harbour for cosmetics. Manufacturers and importers must therefore align their product presentation to avoid straying into prohibited therapeutic representations, or accept that different regulatory treatment will follow.

Overlap with labelling and consumer protection rules: The Standard specifies labelling requirements by reference to clauses of AS/NZS 2604:2012 and 1998. Those clause‑level requirements will sit alongside other statutory and regulatory labelling obligations applicable in Australia. Because the Standard prescribes how protection factors and other representations must be stated (Schedule 1 items 1 and 2), there is an interactional effect where multiple labelling rules may apply concurrently. The Standard does not reconcile or supersede obligations that may arise under other laws; it simply adds mandatory clause‑referenced requirements for the listed products.

Implications for trade and import controls: The Standard distinguishes obligations based on whether a product is imported into, or manufactured in, Australia before or on/after 1 August 2018 (Schedule 1 items 1 and 2). That temporal rule requires importers and manufacturers to maintain documentary proof of dates of import or manufacture. It interacts with customs and supply‑chain recordkeeping practices because evidence of the importation or manufacture date determines which version of AS/NZS and which clause set applies.

No express interaction clauses in the text: The Standard does not itself include clauses that expressly harmonise, displace or carve out obligations imposed by other statutes. It does not state which instrument prevails in case of conflict. The practical consequence is that regulated parties must read the Standard alongside the parent Act and any other applicable regulatory regimes (for example labelling, consumer protection and therapeutic goods regimes) to ensure comprehensive compliance. The Standard creates mandatory obligations of its own, but it is silent on how those obligations integrate with other statutes beyond being made under the Act.

The compilation includes an endnote that summarises the instrument’s legislative history up to 1 August 2013. The key recorded amendments are as follows.

• Original registration and commencement: The Cosmetics Standard 2007 was registered on the Federal Register of Legislative Instruments on 14 September 2007 and commenced on 17 September 2007 (Endnote 1, table). The standard’s name is given in s 1.

• Sunscreen amendment 2013: A substantive amendment titled Cosmetics Amendment (Sunscreen) Standard 2013 is recorded. That amendment was registered on 21 June 2013 (FRLI F2013L01110) and commenced on 1 August 2013 (Endnote 1). Endnote 2 records that s 3 and Schedule 1 were amended by F2013L01110 (Endnote 2: "s. 3.................... am. F2013L01110" and "Schedule 1............... am. F2013L01110").

• Compilation date: The compiled instrument includes the Standard as amended and in force on 1 August 2013; the compilation was prepared on 1 August 2013 (compilation header). The compilation includes the changes made by the 2013 Sunscreen amendment.

The endnotes also explicitly state there are no uncommenced amendments (Endnote 3) and no misdescribed amendments (Endnote 4) as of the compilation date. The text of s 3 in the compiled instrument reflects the insertions made by the 2013 amendment, particularly the defined reference to AS/NZS 2604:2012 and its publication date.

Operationally, the amendment history explains why Schedule 1 incorporates two AS/NZS versions and why a temporal rule is set for products imported or manufactured before 1 August 2018 versus on or after that date (Schedule 1 items 1 and 2). The compilation does not include any subsequent amendments beyond the 2013 Sunscreen Standard amendment.

The compiled instrument and its endnotes do not record any litigation history. The Standard as compiled includes no references to court decisions, no notes of judicial interpretation, and no citations to cases. The endnotes set out the legislative history and amendment history only; there is no entry in the compilation that identifies challenges, judicial review proceedings, or case law applying the Standard.

Accordingly, based on the instrument text and the compilation endnotes provided, there are no reported cases or litigation matters recorded against the Cosmetics Standard 2007 in this compilation. Any litigation that might relate to the Standard would need to be identified from external judicial databases or later compilations; the Standard’s compiled text and endnotes themselves contain no litigation entries.

Several practical traps and compliance pitfalls arise from the Standard’s precise drafting and its reliance on external standards.

Dual‑version references and transitional cut‑off: For some product types (Schedule 1 items 1 and 2), the Schedule allows compliance with AS/NZS 2604:1998 or AS/NZS 2604:2012 for products imported into, or manufactured in, Australia before 1 August 2018, but requires AS/NZS 2604:2012 for products on or after 1 August 2018 (Schedule 1 items 1 and 2). This creates a documentary burden to prove manufacture or import date. Businesses cannot assume a single standard version applies across their product ranges; they must segment stock and records by date and apply the correct clause set accordingly.

Clause‑specific obligations in external standards: The Schedule does not simply require compliance with AS/NZS 2604 in general terms; it references specific clauses and tables, such as clauses 5, 6, 7.1 and 7.3 of AS/NZS 2604:2012 and clauses 6.2 and 6.3 of AS/NZS 2604:1998 (Schedule 1 items 1 and 2). Compliance therefore requires access to the exact clause text in the private AS/NZS documents. A superficial or generic reading of AS/NZS 2604 will not suffice; suppliers must verify compliance against the precise clause numbering referenced in the Schedule.

Label statement nuance: The Schedule distinguishes between stating a protection factor and stating an equivalent category description. Where a protection factor is stated on the label, post‑2018 products must meet clauses 7.1 and 7.3 of AS/NZS 2604:2012 (Schedule 1 items 1(c) and 2(e)). Parties that use informal or colloquial protection statements (for example, shorthand or non‑standard descriptors) risk non‑compliance if the labelling format does not meet the clause requirements.

Pack size and stability thresholds: For specified skin care products with sunscreen (Schedule 1 item 2(b)(iv)-(iii)), the Schedule caps pack sizes at 300 mL or 300 g and requires an expiry date if the product is not stable for at least 36 months. Manufacturers that produce larger pack sizes or that have stability under 36 months must revise packaging and labelling. The instrument does not define testing methodology for stability within its text; proving stability will require laboratory evidence consistent with recognised protocols, but the Schedule does not state which protocol to use.

Water‑resistance and SPF caps: Schedule 1 item 2(b)(i)-(ii) bans presenting certain skin care products as water‑resistant and presenting them as having an SPF greater than 15. A product that previously marketed itself as "water‑resistant" or as SPF 30, but wishes to be sold within the skin care subcategory governed by item 2, will need to alter formulation or marketing. The wording "presented as" captures labelling, advertising and potentially implied claims, so even promotional claims beyond the physical label may be captured.

Narrow constraints on antimicrobial and procedural use claims: Item 3 lays out an extensive list of prohibited presentations for antibacterial skin products, including use in piercing, use prior to medical contact, use for procedures involving venipuncture or injections, and claims of activity against non‑bacterial microbes. The breadth and specificity of these prohibitions mean that product copywriters and legal reviewers must audit packaging and promotional materials carefully to avoid straying into the enumerated forbidden contexts.

Presentational language triggers enforcement: Several obligations hinge on how the product is "presented" rather than on its formulation alone. That creates a compliance risk because presentation is a question of information communicated to consumers via packaging, labelling, promotional materials, website content and point‑of‑sale materials. Small deviations in marketing collateral can change the regulatory character of the product. Internal compliance procedures must therefore include marketing and advertising review in addition to product testing.

No remedial or sanction clauses in the Standard: Because the Standard contains no penalty or remedial provisions, regulated entities might mistakenly assume there is no enforcement mechanism. In reality, the parent Act governs enforcement. Compliance programmes must therefore address the whole regulatory landscape rather than treating the Standard in isolation.

Access to private standards required: The Standard makes legal compliance contingent on meeting clauses in private, published AS/NZS documents. Regulated entities must procure copies of AS/NZS 2604:1998 and AS/NZS 2604:2012 to determine compliance obligations precisely. Relying on secondary or paraphrased summaries of the AS/NZS clauses risks misapplication because the Schedule references clause numbers and table entries directly.

Temporal scope and stock on hand: The Schedule’s date‑based rules mean that stock produced before the 1 August 2018 cut‑off but placed on the market later may raise questions about applicable standards. Compliance will rest on the statutory phrasing "imported into, or manufactured in, Australia before/on or after 1 August 2018" (Schedule 1 items 1 and 2). Businesses must maintain import and manufacture records and plan stock movements accordingly.

A compliance roadmap grounded in the Standard’s text focuses on classification, documentation, testing, labelling and marketing review.

1. Classify the product precisely against Schedule 1

   • Determine whether your product falls into one of Schedule 1’s listed product categories and product types (face and nail; skin care; antibacterial skin products; anti‑acne; oral hygiene; anti‑dandruff). Section 4 makes compliance contingent on the product being one of the types mentioned in Schedule 1. Use the Schedule’s product type descriptions literally to assign the correct item.

2. Establish the applicable temporal regime

   • For items 1 and 2, determine whether the product was imported into, or manufactured in, Australia before 1 August 2018 or on/after that date, because different AS/NZS versions and clause obligations apply depending on that date (Schedule 1 items 1 and 2). Maintain documentary evidence (production logs, customs import records, invoices) proving manufacture or import date.

3. Obtain the referenced AS/NZS standard versions

   • Secure authenticated copies of AS/NZS 2604:1998 and AS/NZS 2604:2012. The Schedule references specific clauses and tables (for example clauses 5, 6, 7.1, 7.3, Table 1 in clause 5.2 and clause 6.3 of AS/NZS 2604:2012; clauses 6.2 and 6.3 of AS/NZS 2604:1998). Compliance requires verifying your product against the exact clause text.

4. Conduct required performance and stability testing

   • For products that must meet broad‑spectrum performance requirements, perform the tests specified in the AS/NZS clauses cited (Schedule 1 items 1(d) and 2(c)). For products with stability thresholds, obtain stability testing to determine whether the product is stable for at least 36 months; if not, ensure an expiry date/use‑by date appears on the label (Schedule 1 item 2(b)(iii)).

5. Align labelling with clause requirements

   • If the product label states a protection factor, ensure the label meets the clause requirements specified by the Schedule (for example clauses 7.1 and 7.3 of AS/NZS 2604:2012 for post‑2018 products in items 1 and 2). Follow clause‑specified formats for protection factor statements and equivalent category descriptions (Schedule 1 items 1 and 2).

6. Verify pack size and water‑resistance statements

   • For products in Schedule 1 item 2, ensure pack size does not exceed 300 mL or 300 g (item 2(b)(iv)), do not present such products as water‑resistant (item 2(b)(ii)), and do not present them as having a sun protection factor greater than 15 (item 2(b)(i)). Revise packaging and marketing accordingly.

7. Audit claims and presentation for restricted categories

   • For antibacterial skin products (item 3), ensure the product is presented as active only against bacteria and not presented as active against non‑bacterial organisms or for use in medical or procedural contexts listed in item 3(b)(ii)-(vii). For anti‑acne and anti‑dandruff products (items 4 and 6), limit claims to cleansing, moisturising, exfoliating or drying mechanisms. For oral hygiene products (item 5), ensure benefits claimed are consequential on improvements in oral hygiene and do not purport to treat other oral diseases. Audit labels, websites and point‑of‑sale materials for compliance.

8. Maintain supporting documentation

   • Keep records of testing reports, stability studies, formulation documents, label proofs, advertising copy and import/manufacture dates. Because the Schedule ties compliance to clause‑level criteria and to the date of manufacture/import, documentary evidence will be required to demonstrate conformity.

9. Integrate marketing and product development processes

   • Ensure that product development, regulatory, marketing and legal review teams coordinate. Because many obligations hinge on "presentation," marketing collateral must be reviewed against the Schedule. Formulation changes intended to achieve broad‑spectrum performance must be validated by the required tests specified in the AS/NZS clauses.

10. Monitor for regulatory changes and recall pathways

• Although the Standard itself does not set enforcement mechanics, maintain processes to respond to compliance notices or requests from the administering authority under the Act. If corrections to labelling, packaging or claims are required, have recall or corrective action plans ready.

11. Seek specialist advice where ambiguous

• Where the product’s categorisation is borderline or where marketing language could be construed as therapeutic, obtain regulatory legal advice. The Schedule’s prohibition on therapeutic claims (for example item 2(b)(v)) narrows the permissible presentation envelope and may affect classification of the product for other regulatory regimes.

By following a compliance programme that maps the product to the correct Schedule 1 item, confirms the applicable AS/NZS clauses and their version, executes the requisite testing and documentation, and aligns labelling and marketing to the representational constraints in the Schedule, a manufacturer or importer will position itself to demonstrate conformity with the Standard under s 4. The Schedule’s clause‑level specificity makes technical testing and documentary proof the practical means of compliance.